Jingtai Technology has reached a $345 million platform strategic cooperation with Eli Lilly on AI enabled bispecific antibodies

Jingtai Technology（2228.HK）Today, it was announced that its wholly-owned subsidiary, Ailux, a biopharmaceutical research and development innovator driven by artificial intelligence (AI), has partnered with top global pharmaceutical company Eli Lilly（Eli Lilly and Company）Reached a multi-target strategic cooperation and platform authorization agreement,The total value of the agreement can reach up to 345 million US dollars, including tens of millions of dollars in advance payments and recent milestone paymentsLilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies (bispecific antibodies) in multiple therapeutic fields, while utilizing its AI antibody development platform to accelerate research on internal pipelines. This is the second collaboration between Jingtai Technology and Eli Lilly after signing a $250 million AI small molecule drug partnership in 2023,Jingtai Technology has also become one of the few AI drug research and development companies in the world that has established high-level cooperation with international leading pharmaceutical companies in the fields of AI macromolecular biopharmaceuticals and AI small molecule drugsVerify its commercial value once again.

According to the agreement, Lilly can nominate multiple target groups, and Ailux will be responsible for designing and optimizing dual antibody candidate drugs. Ailux is eligible to receive millions of dollars in advance payments and recent milestone payments, as well as subsequent milestone payments for research and development, registration, and commercialization. In addition, Lilly also has the right to obtain Ailux artificial incomeintelligenceThe right to use the dual resistance design platform.

The signing of AI macromolecule research and development cooperation with Eli Lilly in the field of dual antibody isJingtai TechnologyAnother key milestone marks that its intelligent drug development platform has also gained favor from major pharmaceutical companies in the development of AI antibody drugs, especially its AI research and development capabilities for new drug forms such as bispecific antibodies have been internationally recognized.Through the deep integration of artificial intelligence technology and high-throughput experimental technology, Jingtai Technology has focused on deploying dual antibodiesAntibody conjugated drugsThe research and development platform for various next-generation drug forms such as ADC and molecular gels has built a diversified, scalable, and future oriented competitive advantage.In the future, Jingtai Technology will accelerate the cooperation and implementation of AI drug development based on algorithm platforms and research and development models that have been validated by major pharmaceutical companies, and continue to create value for patients, customers, and investors.

Looking back at the development history of Jingtai Technology,It was after reaching a $250 million AI small molecule drug research and development cooperation with Eli Lilly in 2023 that Jingtai's AI small molecule platform capabilities were rapidly validated and developed, and subsequently signed multiple internationally influential collaborations, including a $6 billion partnership with DoveTree founded by legendary biopharmaceutical entrepreneur Gregory Verdine.We have once again reached an agreement with Eli Lilly on bispecific antibodiesResearch and development of AI based macromolecular drugsWe believe that platform strategic cooperation indicates that Jingtai will have more and larger scale orders and achievements in the field of AI macromolecular drugs in the future.

As one of the core drug forms, antibodies surpass small molecule drugs in terms of annual growth rate, proportion of heavyweight drugs, and clinical success rate. Its global drug market size is expected to increase from $288.4 billion in 2025 to $628.5 billion in 2035, and its market share will continue to increase. This collaboration with Eli Lilly for the second time to develop AI antibody drugs marks that Jingtai Technology has become one of the world's scarce comprehensive platforms with both AI small molecule and AI large molecule research and development capabilities, and further consolidates its leading position in the AI pharmaceutical industry. The value and commercialization potential of the platform have jumped to a new dimension.

Ailux is a large molecule drug research and development platform that Jingtai Technology has been focusing on since 2021, and has experienced rapid development and commercialization in the past two years. Ailux, with its wet dry combination research and development model, achieves precise AI antibody drug design and engineering, effectively solving the challenges of high cost and long cycle in drug discovery, and helping pharmaceutical companies explore richer targeting mechanisms and differentiated drug pathways.In the future, Ailux will also have the ability to advance various next-generation antibody drugs designed by AI to later clinical stages, in order to obtain more influential major commercial collaborations.

Relying on the fusion advantages of quantum physics, AI, and high-throughput wet experiment capabilities of Jingtai Technology, Ailux has developed an end-to-end AI biopharmaceutical research and development platform, which can design high-value potential antibody drugs for complex disease mechanisms. This platform is supported by a proprietary multimodal biopharmaceutical database, providing physics based structural modeling, generative design, and exploitability analysis. It is capable of designing antibody molecules that combine innovative functionality, superior efficacy, and ideal drug like characteristics, enabling rapid screening of candidate drugs with high exploitability and market competitiveness. This platform has served multiple top international pharmaceutical companies and has been successfully validated in several research and development projects.

Lilly is our important long-term partnerJingtai Technology CEO Ma Jian saidWe are pleased to extend this deep trust partnership to the field of macromolecular drug research and development, which represents Lilly's recognition of Jingtai Technology's AI platform's ability to create transformative therapies

“Bispecific antibodies are one of the most promising directions in the field of treatment today,”Ailux CEO and Senior Vice President of Jingtai Technology, Li Yi, stated，“The AI solution developed by Ailux can quickly transform single specific antibodies into dual antibodies with excellent therapeutic efficacy and exploitability. We look forward to working together with global biopharmaceutical leader Eli Lilly to drive the next generation of molecules into the clinical stageThat's right

●closeYuAilux●

Ailux is owned by XtalPi Holdings Limited, a Hong Kong listed company, XTALPI， Stock code:2228.HK）Founded and wholly owned, it is an innovative enterprise dedicated to developing advanced biological therapies through AI solutions. As a professional biopharmaceutical research and development platform under Jingtai Technology, Ailux combines proprietary computational models with cutting-edge wet experimental capabilities to overcome traditional non drug targets and design biopharmaceutical molecules with innovative drug potential. The company has a team of over 100 people worldwide and is collaborating with several top biopharmaceutical companies, committed to transforming cutting-edge science into transformative and innovative drugs.